REDUSIS 500 / REDUSIS DS

(Sodium Bicarbonate 500 mg / 1000 mg – Enteric Coated Tablet)

Metabolic Acidosis Correction Therapy in CKD

 PRODUCT INTRODUCTION

Brand Name: REDUSIS 500 / REDUSIS DS
Composition:

• Sodium Bicarbonate 500 mg (EC)
• Sodium Bicarbonate 1000 mg (DS – EC)

Category: Systemic Alkalinizing Agent

CLINICAL BACKGROUND (FOR MR UNDERSTANDING)

In CKD Stage 3–5:

• Kidneys cannot excrete acid efficiently
• Serum bicarbonate falls (<22 mEq/L)
• Metabolic acidosis develops
• Muscle wasting increases
• CKD progression accelerates

👉 Correction of metabolic acidosis slows CKD progression.

MODE OF ACTION (MOA)

• Sodium bicarbonate dissociates → bicarbonate ions released
• Buffers excess hydrogen ions
• Raises serum bicarbonate level
• Corrects metabolic acidosis

Clinical Effects:

✔ Improves muscle protein balance
✔ Slows GFR decline
✔ Reduces bone buffering
✔ Improves nutritional status

INDICATIONS

• Metabolic acidosis in CKD
• Serum bicarbonate <22 mEq/L
• Dialysis patients with acidosis
• Chronic renal tubular acidosis

DOSAGE

• REDUSIS 500: Mild acidosis
• REDUSIS DS (1000 mg): Moderate to severe acidosis

Dose adjusted based on serum bicarbonate levels
As prescribed by nephrologist

FEATURE – ADVANTAGE – BENEFIT (FAB)

🔹 Feature

Enteric-coated sodium bicarbonate tablet

🔹 Advantage

Reduced gastric irritation

🔹 Benefit

Better patient compliance & sustained correction

USP

✔ Enteric-coated formulation
✔ GI-friendly
✔ CKD-specific positioning
✔ Supports dialysis delay strategy
✔ Cost-effective long-term therapy

SAFETY PROFILE

• Monitor sodium levels
• Monitor blood pressure
• Risk of fluid retention in CHF
• Avoid overcorrection (metabolic alkalosis)

 

 

MEGAFORD 160

(Megestrol Acetate 160 mg Tablet)

Appetite Restoration & Cachexia Management Therapy

 PRODUCT INTRODUCTION

Brand Name: MEGAFORD 160
Generic Name: Megestrol Acetate 160 mg
Category:Progestational Appetite Stimulant

CLINICAL BACKGROUND (FOR MR UNDERSTANDING)

Loss of appetite & weight loss common in:

• CKD patients
• Dialysis patients
• Cancer cachexia
• Elderly patients
• Chronic infections
• Post-surgery recovery

Malnutrition leads to:

• Muscle wasting
• Poor immunity
• Delayed recovery
• Poor quality of life

👉 Appetite stimulation improves overall prognosis.

MODE OF ACTION (MOA)

Megestrol Acetate is a synthetic progestin.

Mechanism:

• Stimulates appetite via hypothalamic action
• Increases neuropeptide Y
• Promotes weight gain
• Improves caloric intake
• Has anti-cachectic effect

Clinical Result:

✔ Increased appetite
✔ Weight gain
✔ Improved nutritional status
✔ Better treatment compliance

INDICATIONS

• Cancer cachexia
• CKD-related malnutrition
• Dialysis-related weight loss
• HIV-associated wasting
• Geriatric anorexia
• Chronic illness-related anorexia

DOSAGE

• 160 mg once daily
• Dose may vary as per indication
• As prescribed by physician

FEATURE – ADVANTAGE – BENEFIT (FAB)

🔹 Feature

Potent appetite stimulant (Progestational therapy)

🔹 Advantage

Stimulates central appetite pathways

🔹 Benefit

Improved weight, strength & recovery

USP

✔ Proven appetite stimulant
✔ Effective in cachexia
✔ Once-daily dosing
✔ Improves nutritional compliance
✔ Useful in CKD & oncology segment

 SAFETY PROFILE

• Possible weight gain
• Fluid retention (monitor in cardiac patients)
• Rare thromboembolic risk
• Monitor long-term use

Generally well tolerated under supervision.

1. Key positioning? → Appetite restoration therapy

 

ASTAFEB 40

(Febuxostat 40 mg Tablet)

Structured in the same professional template as your previous products.

📘 ASTAFEB 40 TRAINING MANUAL

Advanced Uric Acid Control in CKD & Metabolic Patients

PRODUCT INTRODUCTION

Brand Name: ASTAFEB 40
Composition: Febuxostat 40 mg

Category: Xanthine Oxidase Inhibitor

TAGLINE & PUNCHLINE

Tagline:
👉Precision Uric Acid Control

Punchline:
👉Lower Uric. Protect the Kidney.

CLINICAL BACKGROUND

In CKD & Metabolic Syndrome patients:

• Hyperuricemia is common
• Uric acid contributes to:
  • Endothelial dysfunction
  • Hypertension
  • CKD progression
  • Gout attacks

Allopurinol limitations:

• Dose adjustment in CKD
• Hypersensitivity risk
• Variable uric acid control

👉 Febuxostat offers more consistent uric acid reduction.

MODE OF ACTION (MOA)

• Selective Xanthine Oxidase Inhibitor
• Blocks conversion of:
  • Hypoxanthine → Xanthine
  • Xanthine → Uric Acid

Clinical Effects:

✔ Reduces serum uric acid
✔ Prevents gout flares
✔ Supports renal protection
✔ Improves endothelial function

INDICATIONS

• Chronic hyperuricemia
• Gout
• CKD patients with high uric acid
• Diabetic nephropathy with hyperuricemia
• Hypertensive patients with elevated uric acid

DOSAGE

• 40 mg once daily
• Dose may be titrated as per physician
• Can be taken with or without food

FEATURE – ADVANTAGE – BENEFIT (FAB)

🔹 Feature

Selective xanthine oxidase inhibition

🔹 Advantage

Stronger uric acid reduction vs conventional therapy

🔹 Benefit

Better gout control & renal protection

USP

✔ More potent uric acid reduction
✔ Effective in CKD (mild–moderate)
✔ Once-daily dosing
✔ Lower hypersensitivity risk vs allopurinol

 SAFETY PROFILE

• Monitor liver function tests
• Initial gout flare possible
• Use cautiously in severe cardiovascular disease
• Dose adjustment based on renal status as per guidelines